Reassure Study: The Real-World Evidence Initiative in Recurrent early pregnancy loss
Written By : Deeksha Bhandari
Published On 2025-12-18 06:30 GMT | Update On 2025-12-18 11:55 GMT
Advertisement
Recurrent early pregnancy loss (REPL) has long been marked by uncertainty, limited evidence, and treatments that offered hope without proven outcomes—resulting in only 87% of pregnancies progressing successfully.
A breakthrough has emerged with Reassure, the first global real-world evidence initiative in REPL: a multicentric observational study involving 828 women across 166 centers.
The study demonstrated that 92.3% of pregnancies continued beyond 20 weeks when treated with dydrogesterone ER 20 mg, representing a major advance in care.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.